Clinical Trial Update: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether adding olanzapine to fosaprepitant dimeglumine improves prevention of chemotherapy-induced nausea and vomiting in cancer patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• fosaprepitant dimeglumine (fosaprepitant dimeglumine)
• olanzapine (olanzapine)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Malignant Neoplasm | Phase 3 | Status: COMPLETED | Results posted: 2023-05-08